BMC Cancer

Table 5 Comparison of the C-index of different models

From: Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma

Variables	Training cohort		Validation cohort
Variables	C-index	95% CI	C-index	95% CI
PFS
Nomogram	0.69	0.65–0.73	0.70	0.65–0.75
TNM stage	0.58	0.55–0.61	0.57	0.53–0.61
TNM stage + LA	0.64	0.60–0.68	0.62	0.56–0.68
TNM stage + EBV	0.65	0.62–0.69	0.65	0.60–0.71
LA + EBV	0.67	0.63–0.72	0.68	0.63–0.74
LA	0.59	0.54–0.63	0.59	0.53–0.65
EBV DNA	0.63	0.59–0.66	0.63	0.58–0.68
OS
Nomogram	0.77	0.71–0.82	0.77	0.70–0.85
TNM stage	0.60	0.57–0.63	0.59	0.55–0.64
TNM stage + LA	0.69	0.64–0.74	0.69	0.62–0.77
TNM stage + EBV	0.66	0.61–0.72	0.67	0.60–0.74
LA + EBV	0.68	0.62–0.74	0.73	0.65–0.81
LA	0.62	0.57–0.68	0.66	0.59–0.73
EBV DNA	0.60	0.54–0.66	0.62	0.55–0.69

Abbreviations: C-index Concordance index, CI Confidence interval, TNM Tumor node metastasis, LA Lymphocyte × albumin, EBV DNA Epstein-Barr virus DNA, PFS Progression-free survival, OS Overall survival

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com